ArticleCrohn's & colitis 3602022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease.
Article in Crohn's & colitis 360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06520397 (Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab), which is not on this map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis.BMJ open gastroenterology · 2026Pooled it
- Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2026Pooled it
- AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.Gastroenterology · 2025Guideline
- Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials.Journal of autoimmunity · 2024Pooled it
- Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.United European gastroenterology journal · 2023Pooled it
- Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine.Drugs - real world outcomes · 2026Article
- Clinical Outcomes During Concurrent Dupilumab and Advanced Immune-Modifying Therapy: A Real-World Cohort Study.Digestive diseases and sciences · 2026Article
- Practical guidelines on medical management of adults with moderate-to-severe inflammatory bowel disease.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- [Advanced Combination Therapy in Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
- A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence.The American journal of case reports · 2026Review
- Who bears the brunt? Geographic, racial and ethnic disparities in mortality trends of inflammatory bowel disorders in the United States.Journal of clinical and translational science · 2026Article
- Identification and validation of candidate biomarkers associated with mitochondria and 18 types of programmed cell death in trigeminal neuralgia: insights from transcriptome sequencing.Frontiers in molecular neuroscience · 2026Article
- Dual Therapy for Complex Inflammatory Bowel Disease: Safety, Clinical and Steroid-Free Response.Clinical and experimental gastroenterology · 2026Article
- Evolution of Advanced Combination Treatment in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2025Article
- Inflammatory Bowel Disease: Understanding Therapeutic Effects of Distinct Molecular Inhibitors as the Key to Current and Future Advanced Therapeutic Strategies.Biomedicines · 2025Review
- Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience.Alimentary pharmacology & therapeutics · 2025Article
- Tissue factor-dependent colitogenic CD4Nature communications · 2025Article
- Dual Therapy in Inflammatory Bowel Disease.Biomolecules · 2025Review
- The Cell-Specific Effects of JAK1 Inhibitors in Ulcerative Colitis.Journal of clinical medicine · 2025Review
- Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions.Journal of clinical medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
Background: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a biologic therapy (SBT) in IBD patients. Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until November 3, 2020, including studies with 2 or more IBD patients on DBT or SBT. Main outcome was safety assessed as pooled rates of adverse events (AEs) and serious AEs (SAEs) for each combination. Effectiveness was reported as pooled rates of clinical, endoscopic, and/or radiographic response and remission. The certainty of evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework. Results: Of the 3688 publications identified, 13 studies (1 clinical trial, 12 observational studies) involving 266 patients on 7 different combinations were included. Median number of prior biologics ranged from 0 to 4, and median duration of follow-up was 16-68 weeks. Most common DBT and SBT were vedolizumab (VDZ) with anti-tumor necrosis factor (aTNF, Conclusions: DBT or SBT appears to be generally safe and may be effective in IBD patients, but the evidence is very uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.